Literature DB >> 22559913

Crosstalk between Toll like receptors and C5a receptor in human monocyte derived DCs suppress inflammatory cytokine production.

Anouk Zaal1, Suzanne N Lissenberg-Thunnissen, Gijs van Schijndel, Diana Wouters, S Marieke van Ham, Anja ten Brinke.   

Abstract

The complement anaphylatoxin, C5a has been implicated in regulation of adaptive immune responses through modulation of APC function as shown mainly in studies in mice. C5a was shown to enhance cytokine production in immature DCs, but the effect of C5a on DC function during DC activation has not been elucidated in human. In this study we investigated the effect of C5a on human monocyte derived DCs when simultaneously stimulated with TLR ligands. While C5a indeed enhanced cytokine production of immature DCs, the addition of C5a inhibited production of IL-12, IL-23 and TNFα induced by various TLR ligands such as LPS, R848 and Pam(3)CSK(4). The inhibitory effect of C5a on LPS induced IL-6 production was less pronounced and LPS induced IL-10 was not affected at all. This indicates that C5aR signaling has a differential effect on human DC differentiation depending on the crosstalk with other receptors. Furthermore we found that C5a affects the LPS induced cytokines in a small time frame, and requires almost concurrent signaling of C5a receptor and TLR4. These data emphasize the complexity of DC regulation by anaphylatoxins. While complement activation may provide proinflammatory signals to immature DCs in the absence of pathogens, the same products may serve to downmodulate or deviate immune responses upon combat against infections. These context depending effects of anaphylatoxins on immune responses may have important implications for the emerging use of complement inhibitors in clinical practice.
Copyright © 2012 Elsevier GmbH. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22559913     DOI: 10.1016/j.imbio.2012.02.014

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  8 in total

1.  Emerging role of C5a/C5aR IL-17A axis in cGVHD.

Authors:  Xiaomei Chen; Peilong Lai; Yulian Wang; Chang He; Suijing Wu; Xin Huang; Suxia Geng; Chengwei Luo; Wei Ling; Lingji Zeng; Peng Li; Zhiwu Jiang; Jianyu Weng; Xin Du
Journal:  Am J Transl Res       Date:  2018-07-15       Impact factor: 4.060

Review 2.  The Role of Damage-Associated Molecular Patterns in Human Diseases: Part I - Promoting inflammation and immunity.

Authors:  Walter G Land
Journal:  Sultan Qaboos Univ Med J       Date:  2015-01-21

Review 3.  More than complementing Tolls: complement-Toll-like receptor synergy and crosstalk in innate immunity and inflammation.

Authors:  George Hajishengallis; John D Lambris
Journal:  Immunol Rev       Date:  2016-11       Impact factor: 12.988

4.  C5a and toll-like receptor 4 crosstalk in retinal pigment epithelial cells.

Authors:  Yi Zhu; Bingling Dai; Yongguo Li; Hui Peng
Journal:  Mol Vis       Date:  2015-09-29       Impact factor: 2.367

Review 5.  Complement System Part II: Role in Immunity.

Authors:  Nicolas S Merle; Remi Noe; Lise Halbwachs-Mecarelli; Veronique Fremeaux-Bacchi; Lubka T Roumenina
Journal:  Front Immunol       Date:  2015-05-26       Impact factor: 7.561

Review 6.  Complement-Dependent Mechanisms and Interventions in Periodontal Disease.

Authors:  George Hajishengallis; Tetsuhiro Kajikawa; Evlambia Hajishengallis; Tomoki Maekawa; Edimara S Reis; Dimitrios C Mastellos; Despina Yancopoulou; Hatice Hasturk; John D Lambris
Journal:  Front Immunol       Date:  2019-03-12       Impact factor: 7.561

7.  Regulatory effects of C5a on IL-17A, IL-17F, and IL-23.

Authors:  Jamison J Grailer; Markus Bosmann; Peter A Ward
Journal:  Front Immunol       Date:  2013-01-09       Impact factor: 7.561

8.  Anaphylatoxin C5a Regulates 6-Sulfo-LacNAc Dendritic Cell Function in Human through Crosstalk with Toll-Like Receptor-Induced CREB Signaling.

Authors:  Anouk Zaal; Miranda Dieker; Manon Oudenampsen; Annelies W Turksma; Suzanne N Lissenberg-Thunnissen; Diana Wouters; S Marieke van Ham; Anja Ten Brinke
Journal:  Front Immunol       Date:  2017-07-14       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.